CHL
MCID: LYM133
MIFTS: 73

Lymphoma, Hodgkin, Classic (CHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphoma, Hodgkin, Classic

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 58 76 39 41
Hodgkin Lymphoma 58 12 77 54 38 30 13 6 15
Hodgkin Disease 58 12 54 76 56 44 74
Hodgkin's Lymphoma 39 12 54 15
Hodgkins Lymphoma 12 17
Chl 58 76
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 74
Hodgkin's Disease of Intrapelvic Lymph Nodes 74
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 12
Stage I Subdiaphragmatic Hodgkin Lymphoma 12
Lymphoma, Hodgkin, Susceptibility to 41
Hodgkin Lymphoma, Susceptibility to 58
Classic Hodgkin Lymphoma 60
Classic Hodgkin Disease 60
Lymphoma, Hodgkin's 54
Hodgkin's Sarcoma 12
Hodgkin's Disease 77
Hl 12

Characteristics:

Orphanet epidemiological data:

60
classic hodgkin lymphoma
Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-5/10000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
lymphoma, hodgkin, classic:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lymphoma, Hodgkin, Classic

NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 98293Disease definitionHodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.EpidemiologyHL is an uncommon cancer with an incidence of about 1/40,000 in North America and Europe. There are about 8500 new cases reported in the U.S. each year.Clinical descriptionHL is comprised of 2 major forms: classical Hodgkin lymphoma (CHL; see this term), seen in 95% of all HL cases, and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL; see this term), seen in only 5% of all HL cases. Disease onset occurs most frequently in young adults (age 15-35) followed by older adults (over the age of 55) and usually begins with the painless swelling of a lymph node in the upper body. Disease can spread to multiple lymph node regions or lymphoid structures and associated systemic symptoms (weight loss > 10% of baseline, fevers, night sweats) are observed in about 20% of patients.EtiologyThe exact cause is unknown but immunological, genetic and environmental factors are thought to be involved.Management and treatmentTreatment with radiotherapy and systemic chemotherapy leads to a very good prognosis. Follow-up physical exams, blood tests and x-rays are needed to check for recurrence and check for any long-term side effects of the toxic treatments. Possible long-term side effects include secondary cancers, infertility, reduced immunity, thyroid problems, heart disease and stroke.PrognosisThe international prognostic score (IPS) is a score given based on the presence of 7 risk factors (male sex, >45 years of age, stage 4 disease, serum albumin 15,000/mm3) at the time of diagnosis. The more factors present, the less favorable the prognosis. The cure rates are 90% for early-stage HL and 70% for advance stage HL.Visit the Orphanet disease page for more resources.

MalaCards based summary : Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to nodular lymphocyte predominant hodgkin lymphoma and hodgkin's lymphoma, lymphocytic depletion. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Viral carcinogenesis. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are fatigue and cellular immunodeficiency

Disease Ontology : 12 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

OMIM : 58 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000)

MedlinePlus : 44 Hodgkin disease is a type of lymphoma. Lymphoma is a cancer of a part of the immune system called the lymph system. The first sign of Hodgkin disease is often an enlarged lymph node. The disease can spread to nearby lymph nodes. Later it may spread to the lungs, liver, or bone marrow. The exact cause is unknown. Hodgkin disease is rare. Symptoms include Painless swelling of the lymph nodes in the neck, armpits, or groin Fever and chills Night sweats Weight loss Loss of appetite Itchy skin To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. Treatment depends on how far the disease has spread. It often includes radiation therapy or chemotherapy. The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Lymphoma, Hodgkin, classic: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Wikipedia : 77 Hodgkin''s lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white... more...

Related Diseases for Lymphoma, Hodgkin, Classic

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1157)
# Related Disease Score Top Affiliating Genes
1 nodular lymphocyte predominant hodgkin lymphoma 34.3 BCL6 PAX5
2 hodgkin's lymphoma, lymphocytic depletion 33.3 ALK PAX5 PTPRC
3 hodgkin's lymphoma, lymphocytic-histiocytic predominance 33.0 BCL6 PTPRC
4 diffuse large b-cell lymphoma 32.7 BCL6 IRF4 MIR155 MIR21
5 primary central nervous system lymphoma 32.7 BCL6 PAX5
6 plasmablastic lymphoma 32.2 BCL6 PTPRC
7 lymphomatoid papulosis 32.1 ALK TIA1
8 sarcoidosis 1 31.8 ALK PTPRC TNFSF8
9 lymphosarcoma 31.6 BCL6 MIR20A PTPRC
10 reticulosarcoma 31.6 ALK BCL6 PAX5 PTPRC TIA1
11 primary mediastinal large b-cell lymphoma 31.6 BCL6 IRF4
12 intraocular lymphoma 31.1 BCL6 PAX5
13 mantle cell lymphoma 30.9 BCL6 PAX5 PTPRC
14 psoriasis 30.5 MIR200A MIR20A MIR21
15 peripheral t-cell lymphoma 30.5 ALK BCL6 TIA1
16 leukemia, acute myeloid 30.4 MIR155 MIR21 MIR374A PTPRC
17 autoimmune lymphoproliferative syndrome, type v 30.4 ALK BCL6 TIA1
18 polymyositis 30.4 MIR155 MIR21
19 lymphoma 30.4 ALK BCL6 KLHDC8B PAX5 PVT1
20 burkitt lymphoma 30.3 BCL6 MIR155 PAX5 PVT1
21 dermatomyositis 30.3 MIR155 MIR21
22 kidney cancer 30.3 MIR20A MIR21 PVT1
23 plasmacytoma 30.3 IRF4 PTPRC PVT1
24 melanoma 30.1 MIR140 MIR200A MIR30B MIR374A PVT1
25 follicular lymphoma 30.1 BCL6 IRF4 MIR155
26 nonalcoholic fatty liver disease 30.1 MIR140 MIR200A MIR21
27 anaplastic large cell lymphoma 30.0 ALK PAX5 PTPRC TNFSF8
28 lymphoma, non-hodgkin, familial 29.9 ALK BCL6 IRF4 PAX5 PTPRC TNFSF8
29 glioma 29.9 MIR140 MIR20A MIR21 PVT1
30 leukemia, acute lymphoblastic 29.9 MIR155 MIR21 PAX5
31 multicentric castleman disease 29.9 BCL6 PAX5
32 lung cancer 29.8 ALK MIR140 MIR155 MIR18A MIR200A MIR20A
33 hepatocellular carcinoma 29.8 MIR155 MIR186 MIR18A MIR200A MIR20A MIR21
34 composite lymphoma 29.7 BCL6 PAX5 TIA1
35 primary effusion lymphoma 29.7 BCL6 IRF4
36 ovarian cancer 29.6 MIR140 MIR155 MIR200A MIR21 MIR374A PVT1
37 b-cell lymphomas 29.6 BCL6 IRF4 MIR20A PAX5 PVT1 TIA1
38 primary cutaneous anaplastic large cell lymphoma 29.5 ALK IRF4 PTPRC TIA1
39 colon lymphoma 29.5 ALK BCL6 IRF4 PTPRC
40 leukemia, chronic lymphocytic 29.5 BCL6 MIR140 PAX5 TNFSF8
41 squamous cell carcinoma, head and neck 29.3 MIR155 MIR186 MIR18A MIR200A MIR21 MIR30B
42 classic hodgkin lymphoma, mixed cellularity type 12.3
43 classic hodgkin lymphoma, lymphocyte-rich type 12.3
44 hodgkin lymphoma, during pregnancy 12.3
45 non-hodgkin lymphoma, during pregnancy 12.3
46 hodgkin lymphoma, childhood 12.2
47 non-hodgkin lymphoma, childhood 12.2
48 hepatic lipase deficiency 12.2
49 hodgkin's lymphoma, nodular sclerosis 11.8
50 hodgkin's lymphoma, mixed cellularity 11.8

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

Human phenotypes related to Lymphoma, Hodgkin, Classic:

60 33 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
2 cellular immunodeficiency 60 33 hallmark (90%) Very frequent (99-80%) HP:0005374
3 lymphoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0002665
4 lymphadenopathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0002716
5 immunodeficiency 33 hallmark (90%) HP:0002721
6 hyperhidrosis 60 33 frequent (33%) Frequent (79-30%) HP:0000975
7 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
8 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
9 weight loss 60 33 frequent (33%) Frequent (79-30%) HP:0001824
10 anorexia 60 33 frequent (33%) Frequent (79-30%) HP:0002039
11 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
12 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
13 poor appetite 60 33 frequent (33%) Frequent (79-30%) HP:0004396
14 ataxia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001251
15 respiratory insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0002093
16 splenomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0001744
17 hepatomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0002240
18 bone marrow hypocellularity 60 33 occasional (7.5%) Occasional (29-5%) HP:0005528
19 peripheral neuropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0009830
20 migraine 60 33 occasional (7.5%) Occasional (29-5%) HP:0002076
21 hemoptysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002105
22 skin rash 60 33 occasional (7.5%) Occasional (29-5%) HP:0000988
23 bone pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002653
24 osteolysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002797
25 dyspnea 33 occasional (7.5%) HP:0002094
26 headache 33 occasional (7.5%) HP:0002315
27 neoplasm 60 Occasional (29-5%)
28 polyclonal elevation of igm 33 HP:0003459
29 hodgkin lymphoma 33 HP:0012189
30 impaired lymphocyte transformation with phytohemagglutinin 33 HP:0003347

Symptoms via clinical synopsis from OMIM:

58
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease

Clinical features from OMIM:

236000

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

FDA approved drugs:

(show top 50) (show all 68)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Afinitor 19 50 EVEROLIMUS Novartis March 2009
3
Akynzeo 19 50 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
4
Aloxi 19 50 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
5
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
6
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
7
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
8
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
9
Emend 19 50 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
10
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
11
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
12
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
13
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
14
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
15
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
16
Herceptin 19 50 TRASTUZUMAB Genentech October 1998
17
Hycamtin 19 50 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
18
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
19
Iressa 19 50 GEFITINIB AstraZeneca May 2003
20
Ixempra 19 50 IXABEPILONE Bristol-Myers Squibb October 2007
21
Kyprolis 19 50 CARFILZOMIB Onyx Pharmaceuticals July 2012
22
Lazanda 19 FENTANYL CITRATE Archimedes June 2011
23
Lupron Depot 19 50 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
24
Lynparza 19 50 OLAPARIB AstraZeneca December 2014
25
Nexavar 19 50 SORAFENIB TOSYLATE Bayer/Onyx December 2005
26
Picato gel 19 INGENOL MEBUTATE LEO Pharma January 2012
27
Plenaxis 19 ABARELIX Praecis Pharmaceuticals December 2003
28
Provenge 19 50 sipuleucel-T Dendreon May 2010
29
Rituxan 19 50 RITUXIMAB Biogen IDEC, Genentech November 1997
30
Sancuso 19 GRANISETRON ProStrakan September 2008
31
Self-examination breast pad 19 Inventive Products on December 22, 1995
32
Stivarga 19 50 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
33
Synercid I.V. 19 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
34
Tarceva 19 50 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
35
Tasigna 19 50 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
36
Torisel 19 50 TEMSIROLIMUS Wyeth May 2007
37
Treanda 19 50 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
38
Trelstar Depot/ Trelstar LA 19 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
39
Valchlor 19 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
40
Vandetanib 19 50 vandetanib AstraZeneca April 2011
41
Xofigo 19 50 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
42
Zoladex 19 50 GOSERELIN ACETATE AstraZeneca January 1996
43
Zuplenz 19 ONDANSETRON Strativa Pharmaceuticals July 2010
44
Zykadia 19 50 CERITINIB Novartis April 2014
45
Aldurazyme 19 LARONIDASE Genzyme May 2003
46
Allegra 19 FEXOFENADINE HYDROCHLORIDE Hoechst Marion Roussel July 1996
47
Avelox I.V. 19 MOXIFLOXACIN HYDROCHLORIDE Bayer November 2001
48
Biaxin XL 19 CLARITHROMYCIN Abbott Laboratories March 2000
49
Cedax 19 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
50
Cefazolin and Dextrose USP 19 CEFAZOLIN SODIUM B Braun Medical July 2000

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 581)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
7
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
9
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
10
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
11
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
12
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
13
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
14
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11056-06-7 5360373
15
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
16
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
17
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
18
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
19
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
20 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Methylprednisolone Acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253

Interventional clinical trials:

(show top 50) (show all 1289)
# Name Status NCT ID Phase Drugs
1 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
3 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
6 A Safety Study of Growth Factor Use in Treatment With Brentuximab Vedotin Plus Chemotherapy Recruiting NCT03646123 Phase 4 brentuximab vedotin;doxorubicin;vinblastine;dacarbazine;G-CSF
7 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
8 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
9 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
10 Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
11 Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
12 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Unknown status NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
13 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
14 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
15 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
16 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
17 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
18 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
19 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
20 Exercise During Chemotherapy for Patients With Hematological Malignancies Unknown status NCT00884364 Phase 3
21 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
22 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
23 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) Completed NCT01034163 Phase 3 Panobinostat;Placebo
24 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
25 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
26 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
27 High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
28 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
29 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
30 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
31 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
32 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
33 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
34 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
35 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
36 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
37 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
38 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
39 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
40 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
41 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
42 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
43 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
44 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
45 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
46 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
47 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
48 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
49 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
50 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Hodgkin, Classic

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Hodgkin Lymphoma 30 KLHDC8B

Anatomical Context for Lymphoma, Hodgkin, Classic

MalaCards organs/tissues related to Lymphoma, Hodgkin, Classic:

42
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Breast, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Hodgkin, Classic

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 5419)
# Title Authors Year
1
Non-Hodgkin lymphoma presenting as acute pancreatitis: A rare occurrence. ( 30656020 )
2019
2
Validation of CD137 Immunohistochemical Stain on Paraffin-Embedded Tissue as a Marker to Facilitate Distinction Between Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, and Anaplastic Large Cell Lymphoma. ( 30816829 )
2019
3
Abbreviated breast magnetic resonance imaging (FAST-MRI): A novel approach to breast cancer screening in patients with previous Hodgkin lymphoma. ( 30786169 )
2019
4
Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma. ( 30790227 )
2019
5
Shared Medical and Environmental Risk Factors in Dry Eye Syndrome, Sjogren's Syndrome, and B-Cell Non-Hodgkin Lymphoma: A Case-Control Study. ( 30805374 )
2019
6
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. ( 30693983 )
2019
7
Parapharyngeal Ganglioneuroma Detected by 18F-FDG PET/CT in a Patient With Hodgkin Lymphoma. ( 30672755 )
2019
8
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. ( 29716416 )
2019
9
Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. ( 30848975 )
2019
10
Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. ( 30701466 )
2019
11
Hepatitis C virus infection is a risk factor for non-Hodgkin lymphoma: A MOOSE-compliant meta-analysis. ( 30882645 )
2019
12
High Prevalence of Hepatitis C Virus among B-Cell Non Hodgkin Lymphoma Patients in Mansoura Region (Egypt), ANRS 12263 Study. ( 30671217 )
2019
13
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. ( 30843894 )
2019
14
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. ( 30859374 )
2019
15
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. ( 30906531 )
2019
16
Cutaneous flushing associated with Hodgkin lymphoma. ( 30906983 )
2019
17
B-cell non-Hodgkin lymphoma discovery after observation of a platelet satellitism around atypical lymphocytes. ( 30907360 )
2019
18
Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype. ( 30916804 )
2019
19
Current Real-Life Results and Future Options of Gemcitabine-Based Salvage Therapy for Relapsed or Refractory Non-Hodgkin Lymphoma. ( 30836362 )
2019
20
Reassessment of Risk Factors and Long-Term Results of Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin Lymphoma. ( 30847943 )
2019
21
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. ( 30850381 )
2019
22
Concomitant occurrence of primary renal non-Hodgkin lymphoma and a colon cancer: A rare case report. ( 30855498 )
2019
23
Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. ( 30858359 )
2019
24
PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. ( 30864146 )
2019
25
Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. ( 30874456 )
2019
26
Overexpression of survivin in pediatric Hodgkin lymphoma tumor cells: Characterization of protein expression and splice-variants transcription profile. ( 30876863 )
2019
27
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. ( 30888476 )
2019
28
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. ( 30890595 )
2019
29
Global patterns and trends in the incidence of non-Hodgkin lymphoma. ( 30895415 )
2019
30
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. ( 30895564 )
2019
31
Primary adrenal Hodgkin lymphoma. ( 30899496 )
2019
32
Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? ( 30899979 )
2019
33
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. ( 30901086 )
2019
34
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. ( 30783096 )
2019
35
CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients. ( 30784033 )
2019
36
Duvelisib in indolent non-Hodgkin lymphoma. ( 30799261 )
2019
37
American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma. ( 30802809 )
2019
38
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. ( 30808874 )
2019
39
7OPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). ( 30810203 )
2019
40
Pregnancy Screening and Contraceptive Counseling in Young Women with Hodgkin Lymphoma: A Single Center Retrospective Review. ( 30811262 )
2019
41
Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. ( 30811291 )
2019
42
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. ( 30811293 )
2019
43
Transformation of a splenic marginal zone lymphoma into classic Hodgkin lymphoma. ( 30814198 )
2019
44
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. ( 30815024 )
2019
45
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. ( 30816618 )
2019
46
Single Nucleotide Polymorphisms in MIR143 Contribute to Protection Against Non-Hodgkin Lymphoma (NHL) in Caucasian Populations. ( 30818878 )
2019
47
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. ( 30820940 )
2019
48
Non-Hodgkin lymphoma in people with HIV. ( 30826280 )
2019
49
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. ( 30826282 )
2019
50
Prognostic Significance of IL-6 in Hodgkin Lymphoma. ( 30830568 )
2019

Variations for Lymphoma, Hodgkin, Classic

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh37 Chromosome 3, 49209095: 49209095
2 KLHDC8B NM_173546.2(KLHDC8B): c.-158C> T single nucleotide variant Pathogenic rs387906223 GRCh38 Chromosome 3, 49171662: 49171662

Cosmic variations for Lymphoma, Hodgkin, Classic:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM584 NRAS skin,arm,malignant melanoma,nodular c.182A>G p.Q61R 1:114713908-114713908 0
2 COSM580 NRAS skin,arm,malignant melanoma,nodular c.181C>A p.Q61K 1:114713909-114713909 0
3 COSM5761 CTNNB1 skin,neck,malignant melanoma,nodular c.131C>T p.P44L 3:41224643-41224643 0
4 COSM476 BRAF skin,neck,malignant melanoma,nodular c.1799T>A p.V600E 7:140753336-140753336 0

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

7 (show top 50) (show all 204)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Lymphoma, Hodgkin, Classic

Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.

Pathways for Lymphoma, Hodgkin, Classic

Pathways related to Lymphoma, Hodgkin, Classic according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 Viral carcinogenesis hsa05203
3 Epstein-Barr virus infection hsa05169

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 BCL6 IRF4 PAX5 PTPRC
2 11.64 MIR155 MIR18A MIR200A MIR20A MIR21 MIR30B
3 10.86 BCL6 PAX5 PTPRC

GO Terms for Lymphoma, Hodgkin, Classic

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR140 MIR155 MIR186 MIR18A MIR20A MIR21
2 micro-ribonucleoprotein complex GO:0035068 9.28 MIR140 MIR155 MIR186 MIR200A MIR20A MIR21

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 miRNA mediated inhibition of translation GO:0035278 9.58 MIR155 MIR20A MIR21
2 positive regulation of sprouting angiogenesis GO:1903672 9.52 MIR155 MIR30B
3 negative regulation of stress fiber assembly GO:0051497 9.51 MIR20A MIR21
4 positive regulation of cardiac muscle hypertrophy GO:0010613 9.49 MIR155 MIR21
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.48 MIR20A MIR21
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.46 MIR140 MIR21
7 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.43 IRF4 PTPRC
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.37 MIR155 MIR20A
9 positive regulation of activated T cell proliferation GO:0042104 9.33 MIR155 MIR21 MIR30B
10 regulation of B cell receptor signaling pathway GO:0050855 9.32 PAX5 PTPRC
11 gene silencing by miRNA GO:0035195 9.32 MIR140 MIR155 MIR186 MIR18A MIR200A MIR20A
12 positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching GO:1905932 9.26 MIR140 MIR18A
13 negative regulation of regulatory T cell differentiation GO:0045590 9.13 MIR155 MIR21 MIR30B

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR140 MIR155 MIR18A MIR200A MIR20A MIR21

Sources for Lymphoma, Hodgkin, Classic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....